We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Recruiting, Not yet recruiting, Available Studies | Ulcerative Colitis | Abbvie [Lead] | M14-033
Previous Study | Return to List | Next Study

Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis

This study is currently recruiting participants.
Verified October 2017 by AbbVie
Sponsor:
ClinicalTrials.gov Identifier:
NCT02065622
First Posted: February 19, 2014
Last Update Posted: October 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie
  Purpose
To evaluate safety and efficacy of two dosing regimens in achieving clinical remission in subjects with moderately to severely active Ulcerative Colitis.

Condition Intervention Phase
Ulcerative Colitis Drug: Adalimumab Other: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Proportion of subjects achieving clinical remission (per full Mayo Score) [ Time Frame: Week 8 ]
  • Proportion of week 8 responders (per full Mayo Score) achieving clinical remission (per full Mayo score) [ Time Frame: week 52 ]

Secondary Outcome Measures:
  • Proportion of Week 8 responders (per full Mayo Score) achieving endoscopic improvement (endoscopic subscore of 0 or 1) [ Time Frame: Week 52 ]
  • Proportion of subjects achieving endoscopic improvement (endoscopic subscore of 0 or 1) [ Time Frame: week 8 ]

Estimated Enrollment: 940
Study Start Date: March 27, 2014
Estimated Study Completion Date: May 15, 2019
Estimated Primary Completion Date: May 15, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard Induction Dose
Standard Induction Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Higher Induction Dose
Higher Induction Dose
Drug: Adalimumab
Other Name: Humira
Active Comparator: Standard Maintenance Dose
Standard Maintenance Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Higher Maintenance Dose
Higher Maintenance Dose
Drug: Adalimumab
Other Name: Humira
Other: Placebo
Experimental: Experimental Maintenance Dose
Experimental Maintenance Dose
Drug: Adalimumab
Other Name: Humira

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.
  • Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral corticosteroids or immunosuppressants or both.

Exclusion Criteria:

  • Subject with Crohn's disease (CD) or indeterminate colitis (IC).
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
  • Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
  • Chronic recurring infections or active Tuberculosis (TB).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02065622


Contacts
Contact: AbbVie_Call Center 847-283-8955 abbvieclinicaltrials@abbvie.com

  Show 166 Study Locations
Sponsors and Collaborators
AbbVie
Investigators
Study Director: Jasmina Kalabic, MD AbbVie
  More Information

Additional Information:
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02065622     History of Changes
Other Study ID Numbers: M14-033
2013-001682-16 ( EudraCT Number )
First Submitted: February 17, 2014
First Posted: February 19, 2014
Last Update Posted: October 11, 2017
Last Verified: October 2017

Keywords provided by AbbVie:
Ulcerative Colitis

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents